These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 17998817)
21. Prognostic role of APC and RASSF1A promoter methylation status in cell free circulating DNA of operable gastric cancer patients. Balgkouranidou I; Matthaios D; Karayiannakis A; Bolanaki H; Michailidis P; Xenidis N; Amarantidis K; Chelis L; Trypsianis G; Chatzaki E; Lianidou ES; Kakolyris S Mutat Res; 2015 Aug; 778():46-51. PubMed ID: 26073472 [TBL] [Abstract][Full Text] [Related]
22. Aberrant promoter hypermethylation in serum DNA from patients with silicosis. Umemura S; Fujimoto N; Hiraki A; Gemba K; Takigawa N; Fujiwara K; Fujii M; Umemura H; Satoh M; Tabata M; Ueoka H; Kiura K; Kishimoto T; Tanimoto M Carcinogenesis; 2008 Sep; 29(9):1845-9. PubMed ID: 18632757 [TBL] [Abstract][Full Text] [Related]
23. [Detection and significance of APC gene promoter hypermethylation in serum of breast cancer patients]. Zhang JJ; Ouyang T; Wan WH; Xu GW; Deng GR Ai Zheng; 2007 Jan; 26(1):44-7. PubMed ID: 17222366 [TBL] [Abstract][Full Text] [Related]
24. Aberrant promoter hypermethylation and genomic hypomethylation in tumor, adjacent normal tissues and blood from breast cancer patients. Cho YH; Yazici H; Wu HC; Terry MB; Gonzalez K; Qu M; Dalay N; Santella RM Anticancer Res; 2010 Jul; 30(7):2489-96. PubMed ID: 20682973 [TBL] [Abstract][Full Text] [Related]
25. DNA methylation patterns of RAR-β2 and RASSF1A gene promoters in FNAB samples from Greek population with benign or malignant breast lesions. Kougioumtsidou N; Vavoulidis E; Nasioutziki M; Symeonidou M; Pratilas GC; Mareti E; Petousis S; Chatzikyriakidou A; Grimbizis G; Theodoridis T; Miliaras D; Dinas K; Zepiridis L Diagn Cytopathol; 2021 Jan; 49(1):153-164. PubMed ID: 32530576 [TBL] [Abstract][Full Text] [Related]
26. Association between HIC1 and RASSF1A promoter hypermethylation with MTHFD1 G1958A polymorphism and clinicopathological features of breast cancer in Iranian patients. Rasti M; Tavasoli P; Monabati A; Entezam M Iran Biomed J; 2009 Oct; 13(4):199-206. PubMed ID: 19946345 [TBL] [Abstract][Full Text] [Related]
27. Protein expression and methylation of MGMT, a DNA repair gene and their correlation with clinicopathological parameters in invasive ductal carcinoma of the breast. Asiaf A; Ahmad ST; Malik AA; Aziz SA; Rasool Z; Masood A; Zargar MA Tumour Biol; 2015 Aug; 36(8):6485-96. PubMed ID: 25820821 [TBL] [Abstract][Full Text] [Related]
28. Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients. Ibanez de Caceres I; Battagli C; Esteller M; Herman JG; Dulaimi E; Edelson MI; Bergman C; Ehya H; Eisenberg BL; Cairns P Cancer Res; 2004 Sep; 64(18):6476-81. PubMed ID: 15374957 [TBL] [Abstract][Full Text] [Related]
29. Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel. Dulaimi E; Uzzo RG; Greenberg RE; Al-Saleem T; Cairns P Clin Cancer Res; 2004 Mar; 10(6):1887-93. PubMed ID: 15041703 [TBL] [Abstract][Full Text] [Related]
30. Methylated DNA and total DNA in serum detected by one-step methylation-specific PCR is predictive of poor prognosis for breast cancer patients. Fujita N; Nakayama T; Yamamoto N; Kim SJ; Shimazu K; Shimomura A; Maruyama N; Morimoto K; Tamaki Y; Noguchi S Oncology; 2012; 83(5):273-82. PubMed ID: 22964822 [TBL] [Abstract][Full Text] [Related]
31. CpG island methylator phenotype of multigene in serum of sporadic breast carcinoma. Jing F; Yuping W; Yong C; Jie L; Jun L; Xuanbing T; Lihua H Tumour Biol; 2010 Aug; 31(4):321-31. PubMed ID: 20490964 [TBL] [Abstract][Full Text] [Related]
32. Tumor-specific methylation in bronchial lavage for the early detection of non-small-cell lung cancer. Kim H; Kwon YM; Kim JS; Lee H; Park JH; Shim YM; Han J; Park J; Kim DH J Clin Oncol; 2004 Jun; 22(12):2363-70. PubMed ID: 15197197 [TBL] [Abstract][Full Text] [Related]
33. Impact of RASSF1A gene methylation on clinico-pathological features of tumor and non-tumor tissue of breast cancer. Gupta V; Agarwal P; Deshpande P Ann Diagn Pathol; 2021 Jun; 52():151722. PubMed ID: 33621744 [TBL] [Abstract][Full Text] [Related]
34. RASSF1A promoter methylation in high-grade serous ovarian cancer: A direct comparison study in primary tumors, adjacent morphologically tumor cell-free tissues and paired circulating tumor DNA. Giannopoulou L; Chebouti I; Pavlakis K; Kasimir-Bauer S; Lianidou ES Oncotarget; 2017 Mar; 8(13):21429-21443. PubMed ID: 28206954 [TBL] [Abstract][Full Text] [Related]
35. Aberrant methylation of RASSF1A in plasma DNA before breast cancer diagnosis in the Breast Cancer Family Registry. Yazici H; Terry MB; Cho YH; Senie RT; Liao Y; Andrulis I; Santella RM Cancer Epidemiol Biomarkers Prev; 2009 Oct; 18(10):2723-5. PubMed ID: 19755643 [TBL] [Abstract][Full Text] [Related]
36. Clinical significance of Stratifin, ERalpha and PR promoter methylation in tumor and serum DNA in Indian breast cancer patients. Mirza S; Sharma G; Parshad R; Srivastava A; Gupta SD; Ralhan R Clin Biochem; 2010 Mar; 43(4-5):380-6. PubMed ID: 19961842 [TBL] [Abstract][Full Text] [Related]
37. Clinical significance of promoter hypermethylation of RASSF1A, RARbeta2, BRCA1 and HOXA5 in breast cancers of Indian patients. Bagadi SA; Prasad CP; Kaur J; Srivastava A; Prashad R; Gupta SD; Ralhan R Life Sci; 2008 Jun; 82(25-26):1288-92. PubMed ID: 18538349 [TBL] [Abstract][Full Text] [Related]
38. Quantitative detection of RASSF1A DNA promoter methylation in tumors and serum of patients with serous epithelial ovarian cancer. Bondurant AE; Huang Z; Whitaker RS; Simel LR; Berchuck A; Murphy SK Gynecol Oncol; 2011 Dec; 123(3):581-7. PubMed ID: 21955482 [TBL] [Abstract][Full Text] [Related]
39. Promoter methylation of RASSF1A, RARbeta and DAPK predict poor prognosis of patients with malignant mesothelioma. Fischer JR; Ohnmacht U; Rieger N; Zemaitis M; Stoffregen C; Kostrzewa M; Buchholz E; Manegold C; Lahm H Lung Cancer; 2006 Oct; 54(1):109-16. PubMed ID: 16893590 [TBL] [Abstract][Full Text] [Related]
40. Oncosuppressor methylation: a possible key role in colon metastatic progression. Tommasi S; Pinto R; Petriella D; Pilato B; Lacalamita R; Santini D; Zito F; Colucci G; Paradiso A; Silvestris N J Cell Physiol; 2011 Jul; 226(7):1934-9. PubMed ID: 21506124 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]